Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsimberidou, Funda Meric-Bernstam, Ecaterina E Dumbrava
{"title":"激素受体阳性乳腺癌伴共济失调-毛细血管扩张突变患者脑转移的多学科治疗。","authors":"Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsimberidou, Funda Meric-Bernstam, Ecaterina E Dumbrava","doi":"10.36401/JIPO-22-33","DOIUrl":null,"url":null,"abstract":"<p><p>Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except <i>for BRCA1/2</i> mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.</p>","PeriodicalId":16081,"journal":{"name":"Journal of Immunotherapy and Precision Oncology","volume":"6 3","pages":"158-161"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/50/i2590-017X-6-3-158.PMC10448731.pdf","citationCount":"0","resultStr":"{\"title\":\"Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.\",\"authors\":\"Anca Chelariu-Raicu, Sarina A Piha-Paul, Mariana Chavez-MacGregor, Jason Johnson, Raymond Sawaya, Mary Frances McAleer, Alissa Nguyen, Audrey Hartnett, Apostolia M Tsimberidou, Funda Meric-Bernstam, Ecaterina E Dumbrava\",\"doi\":\"10.36401/JIPO-22-33\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except <i>for BRCA1/2</i> mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.</p>\",\"PeriodicalId\":16081,\"journal\":{\"name\":\"Journal of Immunotherapy and Precision Oncology\",\"volume\":\"6 3\",\"pages\":\"158-161\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/50/i2590-017X-6-3-158.PMC10448731.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Immunotherapy and Precision Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36401/JIPO-22-33\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunotherapy and Precision Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36401/JIPO-22-33","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation.
Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes. Currently, except for BRCA1/2 mutation carriers with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, there is inadequate identification of predictive biomarkers of response. We present a 57-year-old woman with metastatic breast cancer, hormone-receptor-positive, HER2 negative with a germline ataxia-telangiectasia mutation with a large brain metastasis with clinical benefit to talazoparib. This case report exemplifies the importance of the multidisciplinary management of patients with brain metastases and personalized biomarker selected treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
